Such a wise statement. #BidenHarris2020 #pandemic

How does your drug plan compare? Read the IMC Analysis of Private Drug Claim Cost Drivers (2016–2019) ow.ly/yt4B50Dbxs1

Ensure you understand your prior authorization program to manage potential risks: ow.ly/tTvg50Dcpvo via Benefits Canada

A great read from Benefits Canada that speaks to the need for specialty drug prior authorization – when prior authorization is delayed or declined, plan members' conditions can worsen. Learn more 👉 bit.ly/38OxiNo

The private-payer perspective matters when assessing the value of a medication – and pharmacoeconomic analysis can be a tool in the private-payer decision making process. Learn more from the Benefits Canada 2020 Face to Face Drug Plan Management Forum. 👉 bit.ly/3bTxEE9

IQVIA Canada PRA subscribers – check out the May 2021 issue for 2 articles I co-authored: (1) BC - Private and Public Payer Integration (with Brad Millson and Tommy Lan) (2) Breaking Down the Facts About Private Drug Plan Costs (with Joe Farago)

.Benefits Canada 2021 CLC on Drug Plan Partnerships examined the evolution of health economics & formulary decision-making in Canadian private drug plans. Managed formularies help manage drug plan costs, but also present potential financial & legal risks benefitscanada.com/microsite/bene…

.IQVIA Canada PRA Subscribers check out the August 2021 issue for my article on gsc Green Shield Canada's Biosimilar Transition Program.

Suzanne Lepage & Lindy Forte provide thoughtful insight into the importance of transparency in the Private Payer's HTA process at today's #CADTHSymp breakfast session.

The PLAN SPONSORS GUIDE TO DIABETES provides education and resources on how to support plan members living with diabetes or caregivers of people with diabetes. I learned so much writing this guide, and I hope you do too! benefitscanada.com/microsite/bene…

PGx testing may be included in employee benefits plans; however, there is significant variability between providers and tests. This guide gives practical guidance on selecting a provider. I learned a lot working on this project, and I hope you do too. ow.ly/ZMFN50GUuyg

My article in the November 2021 issue of IQVIA PRA includes profiles of several Canadian private payers to help PRA subscribers improve partnerships, submissions and ongoing collaborations. IQVIA

Gene therapies could reshape the way genetic diseases are managed because they target the underlying cause of genetic disease rather than just treating complex medical conditions. I learned a lot writing this for Benefits Canada and I hope you do to. online.fliphtml5.com/fuinl/ikrd/#p=…

Catch up on the coverage from Benefits Canada 2021 Face to Face in Drug Plan Management Forum benefitscanada.com/benefits/healt…

Catch up on Benefits Canada Chronic Disease at Work conference coverage benefitscanada.com/microsite/chro…

At Express Scripts Canada, we're tracking medications and technologies that improves the health of Canadians. If you'd like an in-depth view, download your copy of our 2022 Drug Trend Report here: bit.ly/37kd4N2 #HR #PBM #Benefits #TPA

Honoured to author the private payer section of IQVIA Canada PharmaFocus report again this year. (Subscription Required)

The Plan Sponsor's Guide to Rare Diseases addresses many of the issues that impact Canadian private plans. I learned a lot by working on this and hope you do too. benefitscanada.com/microsite/the-… via Benefits Canada #RareDisease #benefits

At Benefits Canada Canadian Leadership Council on Drug Plan Partnerships we brought together plan advisors to discuss innovation in drug development and its impact on Canadian private drug plans. Would love to hear your thoughts. benefitscanada.com/microsite/bene…

How plan sponsors, insurers are considering coverage of weight-loss drugs amid rising use of Ozempic via Benefits Canada lnkd.in/gH4-W_Uj